Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 20Stomach Neoplasms 2Inflammatory Breast Neoplasms 2Rectal Neoplasms 1Neoplastic Cells, Circulating 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Invasive Breast Cancer 1HER2 Positive Breast Cancer 1Elderly Metastatic Breast Cancer Population 1Colorectal Neoplasms 1Colonic Neoplasms 1Cardiotoxicity 1Breast Neoplasms, Male 1Anatomic Stage IV Breast Cancer AJCC v8 1Anatomic Stage II Breast Cancer AJCC v8 1Advanced Cancer 1

Interventions

trastuzumab biosimilar HLX02 1pertuzumab 1Trastuzumab 1Taxes 1Surgical Procedures, Operative 1Radiotherapy 1Radiation 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Mastectomy, Segmental 1Mastectomy 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Drug Therapy 1Docetaxel 1Albumin-Bound Paclitaxel 1Ado-Trastuzumab Emtansine 12C4 antibody 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Anatomic Stage II Breast Cancer AJCC v8 × Trastuzumab × Clear all
NCT04266249 2026-05-05

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
2,175 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡